PCSK9 and atherosclerosis: Alirocumab, a PCSK9 inhibitor, showed significant LDL-C reduction and early lipid stabilization in the EPIC-STEMI trial when administered during primary PCI, which may synergize with anti-inflammatory therapies in the management of atherosclerosis.20 PCSK9 inhibitors, such as alirocumab and evolocumab, are biological agents that not only provide potent lipid-lowering effects but also modulate inflammation through indirect mechanisms.